Compare — Georgia Financials

panel 2026-09-21Ask

FY 2023 · GEL thousands · companies ordered by revenueXLSX

Line item	Sama Holding	Inparm	New Georgia - 555	Denk Pharma Caucasus	Megaveti
Total Revenue	23,750	23,148	22,814	20,487	11,860
Total COGS	-14,956	-20,361	-13,564	-11,896	-6,211
Gross Profit	8,794	2,787	9,250	8,591	5,649
Gross Margin	37.0%	12.0%	40.5%	41.9%	47.6%
Total Operating Expenses	-84	-42	-8,478	-7,758	-2,345
EBITDA	8,711	2,745	772	833	3,304
EBITDA Margin	36.7%	11.9%	3.4%	4.1%	27.9%
Total D&A	-9	-12	0	-236	-98
EBIT / Operating Income	8,702	2,733	772	597	3,205
Total Other Income	189	179	—	-219	103
Profit Before Tax	8,890	2,912	654	426	3,308
Total Income Tax	0	0	0	0	-318
Net Profit / (Loss)	8,890	2,912	654	589	2,990
Net Margin	37.4%	12.6%	2.9%	2.9%	25.2%
Total Interest Expense	—	—	-118	—	—
Total Interest Income	—	—	—	47	—

Peer percentile within sector

Rank on

Company	Sector	EBITDA margin · FY 2023	Percentile	Sector n
Sama Holding	Pharma	36.7%	83rd pct	123
Megaveti	Pharma	27.9%	70th pct	123
Inparm	Pharma	11.9%	41st pct	123
Denk Pharma Caucasus	Pharma	4.1%	24th pct	123
New Georgia - 555	Pharma	3.4%	20th pct	123

Percentile is within each company's own sector across the whole FY2023 cross-section (1st–100th; higher = larger value). Companies with no sector, or no filing for the year, are not ranked.